Idorsia Ltd. (IDRSF)
5.38
-0.02
(-0.37%)
USD |
OTCM |
Oct 02, 16:00
Idorsia Net Income (Quarterly) : -135.44M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -135.44M |
| March 31, 2026 | -58.31M |
| December 31, 2025 | -97.29M |
| September 30, 2025 | -107.07M |
| June 30, 2025 | -13.76M |
| March 31, 2025 | 70.21M |
| December 31, 2024 | -95.74M |
| September 30, 2024 | -101.04M |
| June 30, 2024 | -120.04M |
| March 31, 2024 | 34.15M |
| December 31, 2023 | -131.51M |
| September 30, 2023 | 253.59M |
| June 30, 2023 | -214.84M |
| March 31, 2023 | -229.33M |
| December 31, 2022 | -200.00M |
| September 30, 2022 | -223.37M |
| June 30, 2022 | -229.56M |
| March 31, 2022 | -213.84M |
| December 31, 2021 | -272.97M |
| Date | Value |
|---|---|
| September 30, 2021 | -152.02M |
| June 30, 2021 | -152.49M |
| March 31, 2021 | -115.37M |
| December 31, 2020 | -151.53M |
| September 30, 2020 | -128.80M |
| June 30, 2020 | -72.02M |
| March 31, 2020 | -124.22M |
| December 31, 2019 | -143.50M |
| September 30, 2019 | -121.87M |
| June 30, 2019 | -125.41M |
| March 31, 2019 | -107.02M |
| December 31, 2018 | -109.01M |
| September 30, 2018 | -121.30M |
| June 30, 2018 | -81.85M |
| March 31, 2018 | -83.22M |
| December 31, 2017 | 68.29M |
| September 30, 2017 | -74.09M |
| June 30, 2017 | 105.07M |
| March 31, 2017 | -114.60M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 237.40M |
| AC Immune SA | 2.371M |
| CRISPR Therapeutics AG | -91.15M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 66.88M |
| Total Expenses (Quarterly) | 202.32M |
| EPS Diluted (Quarterly) | -0.5293 |
| Enterprise Value | 2.970B |
| Gross Profit Margin (Quarterly) | 72.13% |
| Profit Margin (Quarterly) | -202.5% |
| Earnings Yield | -30.69% |
| Normalized Earnings Yield | -24.51 |